Pages that link to "Q24594382"
Jump to navigation
Jump to search
The following pages link to Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a) (Q24594382):
Displayed 40 items.
- Genome-wide analysis of blood pressure variability and ischemic stroke (Q30410548) (← links)
- Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with [...] (Q33948919) (← links)
- Ancestry and other genetic associations with plasma PCSK9 response to simvastatin (Q34157965) (← links)
- Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation (Q34269364) (← links)
- Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins (Q34453666) (← links)
- Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers (Q34756897) (← links)
- The role of Multidrug Resistance-1 (MDR1) variants in response to atorvastatin among Jordanians. (Q35085937) (← links)
- A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians (Q35511685) (← links)
- CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin (Q35933626) (← links)
- Effects of phenotypic and genotypic factors on the lipid responses to niacin in Chinese patients with dyslipidemia. (Q36152978) (← links)
- THE CHALLENGES IN USING ELECTRONIC HEALTH RECORDS FOR PHARMACOGENOMICS AND PRECISION MEDICINE RESEARCH (Q36485405) (← links)
- Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study (Q36730132) (← links)
- Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. (Q36747275) (← links)
- Positive correlation between variants of lipid metabolism‑related genes and coronary heart disease (Q37048550) (← links)
- Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner. (Q37227150) (← links)
- Lipoprotein(a): resurrected by genetics (Q38045424) (← links)
- Pharmacogenomics of lipid-lowering therapies (Q38112823) (← links)
- Lipid-lowing pharmacogenomics in Chinese patients (Q38129422) (← links)
- Update on lipoprotein(a) as a cardiovascular risk factor and mediator. (Q38132701) (← links)
- Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin (Q38155218) (← links)
- Pharmacogenomics, lipid disorders, and treatment options (Q38203774) (← links)
- RP1-13D10.2 Is a Novel Modulator of Statin-Induced Changes in Cholesterol. (Q38438530) (← links)
- Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. (Q38663481) (← links)
- Seventeen years of statin pharmacogenetics: a systematic review (Q38670109) (← links)
- Personalized medicine: Genetic risk prediction of drug response (Q38756015) (← links)
- The genetics of drug efficacy: opportunities and challenges (Q38773033) (← links)
- Pharmacogenetics of Lipid-Lowering Agents: Precision or Indecision Medicine? (Q38780996) (← links)
- Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis (Q38839978) (← links)
- PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease. (Q39453691) (← links)
- HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals (Q40499193) (← links)
- A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering (Q40817564) (← links)
- Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects (Q42291683) (← links)
- Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A2 formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). (Q47275166) (← links)
- Prospective association of a genetic risk score with major adverse cardiovascular events in patients with coronary artery disease (Q49485833) (← links)
- Association of apolipoprotein E gene polymorphisms with blood lipids and their interaction with dietary factors. (Q53070205) (← links)
- Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials (Q57187342) (← links)
- Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort (Q57822685) (← links)
- ZNF542P is a pseudogene associated with LDL response to simvastatin treatment (Q58737227) (← links)
- Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia (Q88585720) (← links)
- The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change (Q92862394) (← links)